Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
10.94
-0.24 (-2.19%)
Aug 14, 2025, 1:49 PM - Market open
Telix Pharmaceuticals Revenue
In the year 2024, Telix Pharmaceuticals had annual revenue of 783.21M AUD with 55.85% growth. Telix Pharmaceuticals had revenue of 209.62M in the quarter ending December 31, 2024, with 48.82% growth.
Revenue (ttm)
783.21M AUD
Revenue Growth
+55.85%
P/S Ratio
7.78
Revenue / Employee
1,887,246 AUD
Employees
415
Market Cap
3.77B undefined
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 783.21M | 280.66M | 55.85% |
| Dec 31, 2023 | 502.55M | 342.45M | 213.90% |
| Dec 31, 2022 | 160.10M | 152.50M | 2,007.64% |
| Dec 31, 2021 | 7.60M | 2.38M | 45.71% |
| Dec 31, 2020 | 5.21M | 1.73M | 49.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TLX News
- 2 days ago - Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena – Hagens Berman - GlobeNewsWire
- 5 days ago - Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman - GlobeNewsWire
- 14 days ago - TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm - Business Wire
- 15 days ago - Telix H1 2025 Results: Investor Webcast Notification - GlobeNewsWire
- 16 days ago - Telix Pharmaceuticals: Assessing The Market's Pullback On SEC Inquiry - Seeking Alpha
- 23 days ago - Telix Reports $204M Revenue, Up 63% YOY - GlobeNewsWire
- 5 weeks ago - Gozellix Receives Permanent HCPCS Code - GlobeNewsWire
- 7 weeks ago - Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT - GlobeNewsWire